THRX 13.15 Theravance $THRX Hit a 52 week low of 13.05 Currently at 13.15 -0.29 -2.16% With a day low of 13.05 and a total volume of 75,902.
THRX Theravance Recent Headline News
Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - 2 hrs 33 mins ago
MRK: 59.44 (+0.63), AZN: 73.84 (+0.63), AMGN: 162.72 (-0.37), TEVA: 58.20 (+0.16), THRX: 13.10 (-0.34), GSK: 45.54 (+0.38), SNY: 46.68 (+0.49), REGN: 388.41 (+2.44), NVS: 92.23 (-0.40)
Theravance Biopharma Q3 Loss Widens Y/Y, Revenues Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 10:20AM CST
Theravance Biopharma reported a third-quarter 2014 loss of $1.72 per share.
AMAG: 34.55 (-0.36), TBPH: 18.22 (-0.10), GSK: 45.54 (+0.38), THRX: 13.10 (-0.34)
Shares of THRX Down 47.9% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Nov 07, 9:10AM CST
SmarTrend identified a Downtrend for Theravance (NASDAQ:THRX) on July 18th, 2014 at $27.33. In approximately 4 months, Theravance has returned 47.93% as of today's recent price of $14.23.
THRX: 13.10 (-0.34)
5 Stocks With Big Insider Buying in November: NuStar, Huntsman and More
at The Street - Thu Nov 06, 11:45AM CST
Insiders usually buy their own shares for one reason: They think the stock is a bargain and has tremendous upside.
SCCO: 29.99 (+0.11), WRLD: 75.06 (-0.35), NS: 60.29 (+0.15), THRX: 13.10 (-0.34), HUN: 25.03 (+0.10)
Theravance to Present at Two Upcoming Investor Conferences in November
Marketwired - Wed Nov 05, 3:08PM CST
Theravance, Inc. (NASDAQ: THRX) today announced Michael W. Aguiar, President and Chief Executive Officer of Theravance, will be presenting at two upcoming investor conferences in November.
THRXV: 28.00 (+7.07), THRX: 13.10 (-0.34)
Real Money's Brian Sozzi: A Primer on Investing in Retail Stocks
at The Street - Wed Nov 05, 11:38AM CST
Some thoughts on the outlook of the retail sector and what to look for before you invest.
COH: 34.26 (+0.36), TJX: 64.01 (+0.09), NKE: 95.18 (+0.22), TGT: 65.67 (+0.15), WMT: 78.99 (-0.45), HBI: 109.91 (+0.16), THRX: 13.10 (-0.34), KORS: 68.80 (-0.35), GPS: 38.86 (+0.30), RL: 172.16 (+0.24), LULU: 43.10 (-0.20)
InsiderInsights.com Daily Round Up 11/4/14: UFI, SABA, CCI
InsiderInsights - at Seeking Alpha - Wed Nov 05, 8:31AM CST
CCI: 79.64 (-0.27), CBG: 32.08 (+0.27), HGG: 5.47 (+0.02), LLY: 68.31 (-0.04), BA: 124.99 (+0.35), MAR: 76.95 (+0.39), QNST: 4.15 (+0.03), OZRK: 36.35 (-0.25), APO: 23.20 (-0.25), STAA: 8.89 (-0.10), AMBR: 11.05 (-0.40), FSAM: 13.68 (-0.13), WRLD: 75.06 (-0.35), CPLA: 68.72 (-0.45), THRX: 13.10 (-0.34), MSFT: 48.74 (-0.15), UFI: 27.47 (-0.28), AN: 58.35 (+0.45), CRM: 63.89 (-0.56)
FDA accepts BI's Spiriva NDA for asthma
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 12:06PM CST
AZN: 73.84 (+0.63), TEVA: 58.20 (+0.16), GSK: 45.54 (+0.38), THRX: 13.10 (-0.34), SNY: 46.68 (+0.49), REGN: 388.98 (+3.01), NVS: 92.23 (-0.40)
7 Old Dividend Dogs Of Healthcare Aim At 11% To 30.5% October Upsides
Fredrik Arnold - at Seeking Alpha - Mon Nov 03, 11:21AM CST
KND: 20.60 (-0.37), VIVO: 16.87 (-0.36), PETS: 13.61 (+0.06), PFE: 30.17 (-0.03), GSK: 45.54 (+0.38), MR: 31.00 (+0.40), SEM: 13.44 (-0.10), PDLI: 8.14 (+0.21), SNN: 33.69 (+0.23), AZN: 73.84 (+0.63), MRK: 59.44 (+0.63), STJ: 65.87 (+0.17), TRIB: 17.79 (+0.14), ABBV: 63.85 (+0.06), THRX: 13.10 (-0.34), SNY: 46.68 (+0.49)
Theravance (THRX) Falls on Wider-than-Expected Loss in Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:10AM CST
Theravance reported third-quarter 2014 loss of 19 cents per share.
AMAG: 34.55 (-0.36), TBPH: 18.22 (-0.10), GSK: 45.54 (+0.38), THRX: 13.10 (-0.34)
Bayer Q3 Earnings Grow Y/Y on New Product Sales, View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:00AM CST
Bayer's (BAYRY) earnings during the third quarter of 2014 came in at roughly $1.79 per share.
MRK: 59.44 (+0.63), AMAG: 34.55 (-0.36), THRX: 13.10 (-0.34)
Update: GSK Starts Promoting Theravance Drugs More Actively
Early Retiree - at Seeking Alpha - Sat Nov 01, 7:42AM CDT
THRX: 13.10 (-0.34), GSK: 45.55 (+0.39)
More on Theravance Q3 results
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 1:03PM CDT
THRX: 13.10 (-0.34)
Theravance misses Street 3Q forecasts
Automated Insights - Fri Oct 31, 4:04AM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Theravance Inc. (THRX) on Friday reported a third-quarter loss of $21.3 million.
THRXV: 28.00 (+7.07), THRX: 13.10 (-0.34)
Theravance's (THRX) CEO Mike Aguiar on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 10:27PM CDT
THRX: 13.10 (-0.34)
Theravance declares $0.25 dividend
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 5:49PM CDT
THRX: 13.10 (-0.34)
Theravance Has Returned 40.7% Since SmarTrend Recommendation (THRX)
Comtex SmarTrend(R) - Thu Oct 30, 4:38PM CDT
SmarTrend identified a Downtrend for Theravance (NASDAQ:THRX) on July 18th, 2014 at $27.33. In approximately 3 months, Theravance has returned 40.69% as of today's recent price of $16.21.
THRX: 13.10 (-0.34)
Theravance (THRX) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Oct 30, 3:55PM CDT
THRX: 13.10 (-0.34)
Theravance misses by $0.05, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 3:26PM CDT
THRX: 13.10 (-0.34)
Theravance Reports Third Quarter 2014 Financial Results
Marketwired - Thu Oct 30, 3:06PM CDT
Theravance, Inc. (NASDAQ: THRX) today reported financial results for the quarter ended September 30, 2014 and announced that its Board of Directors approved a $0.25 per share cash dividend to be paid on December 23, 2014 to stockholders of record as of the close of business on November 25, 2014. Royalties received on net sales of RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R) from Glaxo Group Limited (GSK) were $4.0 million. Net loss for the third quarter of 2014 was $21.3 million or $0.19 per diluted share. Cash, cash equivalents, marketable securities and current restricted cash totaled $316.5 million as of September 30, 2014.
THRXV: 28.00 (+7.07), THRX: 13.10 (-0.34), TBPH: 18.22 (-0.10)
THRX Theravance Recent Headline News
Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - 2 hrs 33 mins ago
MRK: 59.44 (+0.63), AZN: 73.84 (+0.63), AMGN: 162.72 (-0.37), TEVA: 58.20 (+0.16), THRX: 13.10 (-0.34), GSK: 45.54 (+0.38), SNY: 46.68 (+0.49), REGN: 388.41 (+2.44), NVS: 92.23 (-0.40)
Theravance Biopharma Q3 Loss Widens Y/Y, Revenues Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 10:20AM CST
Theravance Biopharma reported a third-quarter 2014 loss of $1.72 per share.
AMAG: 34.55 (-0.36), TBPH: 18.22 (-0.10), GSK: 45.54 (+0.38), THRX: 13.10 (-0.34)
Shares of THRX Down 47.9% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Nov 07, 9:10AM CST
SmarTrend identified a Downtrend for Theravance (NASDAQ:THRX) on July 18th, 2014 at $27.33. In approximately 4 months, Theravance has returned 47.93% as of today's recent price of $14.23.
THRX: 13.10 (-0.34)
5 Stocks With Big Insider Buying in November: NuStar, Huntsman and More
at The Street - Thu Nov 06, 11:45AM CST
Insiders usually buy their own shares for one reason: They think the stock is a bargain and has tremendous upside.
SCCO: 29.99 (+0.11), WRLD: 75.06 (-0.35), NS: 60.29 (+0.15), THRX: 13.10 (-0.34), HUN: 25.03 (+0.10)
Theravance to Present at Two Upcoming Investor Conferences in November
Marketwired - Wed Nov 05, 3:08PM CST
Theravance, Inc. (NASDAQ: THRX) today announced Michael W. Aguiar, President and Chief Executive Officer of Theravance, will be presenting at two upcoming investor conferences in November.
THRXV: 28.00 (+7.07), THRX: 13.10 (-0.34)
Real Money's Brian Sozzi: A Primer on Investing in Retail Stocks
at The Street - Wed Nov 05, 11:38AM CST
Some thoughts on the outlook of the retail sector and what to look for before you invest.
COH: 34.26 (+0.36), TJX: 64.01 (+0.09), NKE: 95.18 (+0.22), TGT: 65.67 (+0.15), WMT: 78.99 (-0.45), HBI: 109.91 (+0.16), THRX: 13.10 (-0.34), KORS: 68.80 (-0.35), GPS: 38.86 (+0.30), RL: 172.16 (+0.24), LULU: 43.10 (-0.20)
InsiderInsights.com Daily Round Up 11/4/14: UFI, SABA, CCI
InsiderInsights - at Seeking Alpha - Wed Nov 05, 8:31AM CST
CCI: 79.64 (-0.27), CBG: 32.08 (+0.27), HGG: 5.47 (+0.02), LLY: 68.31 (-0.04), BA: 124.99 (+0.35), MAR: 76.95 (+0.39), QNST: 4.15 (+0.03), OZRK: 36.35 (-0.25), APO: 23.20 (-0.25), STAA: 8.89 (-0.10), AMBR: 11.05 (-0.40), FSAM: 13.68 (-0.13), WRLD: 75.06 (-0.35), CPLA: 68.72 (-0.45), THRX: 13.10 (-0.34), MSFT: 48.74 (-0.15), UFI: 27.47 (-0.28), AN: 58.35 (+0.45), CRM: 63.89 (-0.56)
FDA accepts BI's Spiriva NDA for asthma
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 12:06PM CST
AZN: 73.84 (+0.63), TEVA: 58.20 (+0.16), GSK: 45.54 (+0.38), THRX: 13.10 (-0.34), SNY: 46.68 (+0.49), REGN: 388.98 (+3.01), NVS: 92.23 (-0.40)
7 Old Dividend Dogs Of Healthcare Aim At 11% To 30.5% October Upsides
Fredrik Arnold - at Seeking Alpha - Mon Nov 03, 11:21AM CST
KND: 20.60 (-0.37), VIVO: 16.87 (-0.36), PETS: 13.61 (+0.06), PFE: 30.17 (-0.03), GSK: 45.54 (+0.38), MR: 31.00 (+0.40), SEM: 13.44 (-0.10), PDLI: 8.14 (+0.21), SNN: 33.69 (+0.23), AZN: 73.84 (+0.63), MRK: 59.44 (+0.63), STJ: 65.87 (+0.17), TRIB: 17.79 (+0.14), ABBV: 63.85 (+0.06), THRX: 13.10 (-0.34), SNY: 46.68 (+0.49)
Theravance (THRX) Falls on Wider-than-Expected Loss in Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:10AM CST
Theravance reported third-quarter 2014 loss of 19 cents per share.
AMAG: 34.55 (-0.36), TBPH: 18.22 (-0.10), GSK: 45.54 (+0.38), THRX: 13.10 (-0.34)
Bayer Q3 Earnings Grow Y/Y on New Product Sales, View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:00AM CST
Bayer's (BAYRY) earnings during the third quarter of 2014 came in at roughly $1.79 per share.
MRK: 59.44 (+0.63), AMAG: 34.55 (-0.36), THRX: 13.10 (-0.34)
Update: GSK Starts Promoting Theravance Drugs More Actively
Early Retiree - at Seeking Alpha - Sat Nov 01, 7:42AM CDT
THRX: 13.10 (-0.34), GSK: 45.55 (+0.39)
More on Theravance Q3 results
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 1:03PM CDT
THRX: 13.10 (-0.34)
Theravance misses Street 3Q forecasts
Automated Insights - Fri Oct 31, 4:04AM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Theravance Inc. (THRX) on Friday reported a third-quarter loss of $21.3 million.
THRXV: 28.00 (+7.07), THRX: 13.10 (-0.34)
Theravance's (THRX) CEO Mike Aguiar on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 10:27PM CDT
THRX: 13.10 (-0.34)
Theravance declares $0.25 dividend
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 5:49PM CDT
THRX: 13.10 (-0.34)
Theravance Has Returned 40.7% Since SmarTrend Recommendation (THRX)
Comtex SmarTrend(R) - Thu Oct 30, 4:38PM CDT
SmarTrend identified a Downtrend for Theravance (NASDAQ:THRX) on July 18th, 2014 at $27.33. In approximately 3 months, Theravance has returned 40.69% as of today's recent price of $16.21.
THRX: 13.10 (-0.34)
Theravance (THRX) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Oct 30, 3:55PM CDT
THRX: 13.10 (-0.34)
Theravance misses by $0.05, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 3:26PM CDT
THRX: 13.10 (-0.34)
Theravance Reports Third Quarter 2014 Financial Results
Marketwired - Thu Oct 30, 3:06PM CDT
Theravance, Inc. (NASDAQ: THRX) today reported financial results for the quarter ended September 30, 2014 and announced that its Board of Directors approved a $0.25 per share cash dividend to be paid on December 23, 2014 to stockholders of record as of the close of business on November 25, 2014. Royalties received on net sales of RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R) from Glaxo Group Limited (GSK) were $4.0 million. Net loss for the third quarter of 2014 was $21.3 million or $0.19 per diluted share. Cash, cash equivalents, marketable securities and current restricted cash totaled $316.5 million as of September 30, 2014.
THRXV: 28.00 (+7.07), THRX: 13.10 (-0.34), TBPH: 18.22 (-0.10)
